

FACT SHEET

COMPANY PROFILE

Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine. Biotest develops, manufactures and markets plasma proteins and biotherapeutic drugs. Our value chain extends from pre-clinical and clinical development to worldwide marketing and distribution. Biotest manufactures immunoglobulins, clotting factors and albumins which derive from human blood plasma. Biotest also develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest currently employs more than 1,700 people worldwide.

The most important raw material for our pharmaceuticals is human blood plasma, which we process into effective and highly purified drugs in one of our world leading fractionation facilities in Europe. These medications are used to treat life-threatening diseases such as blood coagulation disorders (haemophilia), severe infections and immune system disorders.

MANAGEMENT BOARD



Dr. Michael Ramroth
 Chairman of the Board of
 Management / Chief Financial
 Officer



Dr. Georg Floß
 Chief Operations Officer

SUPERVISORY BOARD

> **Rolf Hoffmann**
 Chairman

> **Tan Yang**
 Dep. Chairman


> **Ms Kerstin Birkhahn**

> **Christine Kreidl**

> **Mr Jürgen Heilmann**

> **Dr. Cathrin Schleussner**


SHARE CHART OF ORDINARY SHARES



KEY DATA OF ORDINARY SHARES

| | |
|-----------------|--|
| ISIN | DE0005227201 |
| WKN | 522 720 |
| Share type | Ordinary |
| Bloomberg Code | BIO@GR |
| Reuters Code | BIOG_p.DE |
| Ticker | BIO |
| Branch | Pharma |
| Index | Prime All Share |
| Segment | Prime Standard |
| Last Dividend | EUR 0.00 (for 2018) |
| No. of shares | 19,785,726 |
| Market Cap | EUR 476.84 mn |
| 52 week high | EUR 27.85 |
| 52 week low | EUR 19.90 |
| Stock exchanges | Regulated market in Frankfurt (Prime Standard); Open Market in Berlin, Dusseldorf, Hamburg/Hanover, Munich, Stuttgart, Tradegate |

SHARE CHART OF PREFERENCE SHARES



KEY DATA OF PREFERENCE SHARES

| | |
|-----------------|--|
| ISIN | DE0005227235 |
| WKN | 522 723 |
| Share type | Preference |
| Bloomberg Code | BIO@GR |
| Reuters Code | BIOG_p.DE |
| Ticker | BIO3 |
| Branch | Pharma |
| Index | Prime All Share |
| Segment | Prime Standard |
| Last Dividend | EUR 0.04 (for 2018) |
| No. of shares | 19,785,726 |
| Market Cap | EUR 435.29 mn |
| 52 week high | EUR 25.80 |
| 52 week low | EUR 19.82 |
| Stock exchanges | Regulated market in Frankfurt (Prime Standard); Open Market in Berlin, Dusseldorf, Hamburg/Hanover, Munich, Stuttgart, Tradegate |

FACT SHEET

ANNUAL FIGURES

| | 2012 | 2013 | 2014 | 2015 | 2016 ¹⁾ | 2017 ¹⁾ | 2018 ¹⁾ |
|-------------------------------------|-------|-------|---------|-------|--------------------|--------------------|--------------------|
| in EUR millions | | | | | | | |
| Sales | 440.0 | 500.8 | 582.0 | 534.6 | 408.0 | 378.1 | 400.3 |
| EBITDA | 76.2 | 85.6 | 85.9 | 59.3 | 58.1 | 13.0 | 35.2 |
| EBIT | 44.7 | 53.8 | 53.4 | 37.3 | 35.2 | (9.3) | 10.6 |
| Profit before tax | 36.5 | 47.8 | 46.9 | 34.8 | 24.0 | (26.0) | (6.0) |
| Net profit | 23.1 | 32.0 | 19.2 | 27.0 | 6.1 | (16.4) | (12.9) |
| Balance Sheet Total | 682.3 | 886.5 | 1,032.6 | 962.7 | 932.8 | 978.5 | 1,042.3 |
| Shareholders' equity | 369.4 | 460.7 | 480.2 | 412.3 | 360.7 | 347.8 | 495.0 |
| Dividend in EUR²⁾ | | | | | | | |
| Ordinary shares | 0.17 | 0.19 | 0.20 | 0.02 | 0.05 | 0.00 | 0.00 |
| Preference shares | 0.19 | 0.21 | 0.22 | 0.04 | 0.07 | 0.04 | 0.04 |
| Staff³⁾ | 1,727 | 1,997 | 2,158 | 2,271 | 1,441 | 1,659 | 1,663 |

All figures according to IFRS

¹⁾ Continuing operations

²⁾ On 15 July 2015 Biotest AG reorganises stock exchange listing due to share split with the ration one to three. By implementing the capital increase and the share split the existing shareholder structure does not change. The share capital of Biotest AG amounted to € 33,767,639.04 before the capital increase and was divided into 6,595,242 ordinary shares and 6,595,242 preference shares without voting rights. Thus, one ordinary or preference share had a proportional amount of the share capital of € 2.56. After the implementation of the capital increase from capital funds by € 5,803,812.96 to € 39,571,452.00 without issuing new shares and the share split, each former holder of one existing ordinary or preference share now holds three ordinary or preference shares with a proportional amount of the share capital of € 1.00. After capital increase and share split the amount of ordinary shares and preference share amounts to each 19,785,726 shares. The previous year's figures have been adjusted to the new amount of shares. 2018: to be proposed to AGM on May 7, 2019

³⁾ in FTEs (Full time equivalents)

SHAREHOLDER STRUCTURE

Ordinary Shares:

Release according to § 21 Abs. 1 WpHG:

89.88% Tiancheng (Germany) Pharmaceutical Holdings AG
(acquisition company of the Creat Group Corporation)

5.00% JO Hambro Capital Management Ltd, London, UK

Preference Shares:

100.00% Free float

FINANCIAL CALENDAR

Aug 14, 2019 Publication of Q2 Report

Nov 14, 2019 Publication of Q3 Report

Biotest AG

Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland

Tel.: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
investor_relations@biotest.de
http://www.biotest.de

Contact Investor Relations

Dr. Monika Buttke
Head of Investor Relations
Telefon: +49 (0) 61 03 / 801 4406
Telefax: +49 (0) 61 03 / 801 347
E-Mail: investor_relations@biotest.de